An international study published in Science Advances has revealed how some metastatic melanoma cells modify their structure to evade the immune system and resist therapies.
At the heart of the research is the protein NFATC2, which appears to play a crucial role in the adaptation process of tumor cells. Targeting this protein could improve the immune system's ability to recognize and attack diseased cells.
The research, which involved researchers from Biogem's Computational Biology laboratory, analyzed biopsies taken from patients involved in the NIBIT-M4 clinical trial, which used a combination of an epigenetic drug (guadecitabine) and an immunotherapy (ipilimumab).
The advanced technologies adopted have allowed us to observe how, in patients responding to therapy, tumor cells become more vulnerable to immune attacks, while in resistant patients some cells maintain the ability to adapt and escape the body's defenses.
This study represents an important step in understanding differences in treatment responses among patients with the same type of melanoma and could lead to the development of more personalized and effective therapeutic strategies against tumor resistance.
Follow Chronicles of Campania
Official channels
.cdc-channel-bar {
width: 100%;
box-sizing: border-box;
display: flex;
align-items: center;
justify-content: space-between;
gap: 14px;
padding: 9px 11px;
background: #ffffff;
border: 0;
border-radius: 14px;
box-shadow:
0 3px 14px rgba(0,0,0,.045);
font-family:
system-ui,
-apple-system,
BlinkMacSystemFont,
"Segoe UI",
sans-serif;
}
/* BRAND */
.cdc-channel-brand {
min-width: 0;
display: flex;
align-items: center;
gap: 9px;
}
.cdc-channel-logo {
width: 34px;
height: 34px;
flex: 0 0 34px;
display: block;
object-fit: contain;
border-radius: 9px;
}
.cdc-channel-text {
min-width: 0;
display: flex;
flex-direction: column;
line-height: 1.15;
}
.cdc-channel-text strong {
color: #171717;
font-size: 13px;
font-weight: 750;
white-space: nowrap;
}
.cdc-channel-text span {
margin-top: 2px;
color: #777;
font-size: 9px;
font-weight: 600;
text-transform: uppercase;
letter-spacing: .055em;
}
/* ICONE */
.cdc-channel-links {
flex: 0 0 auto;
display: flex;
align-items: center;
gap: 7px;
}
.cdc-channel-icon {
width: 36px;
height: 36px;
flex: 0 0 36px;
display: inline-flex;
align-items: center;
justify-content: center;
border-radius: 50%;
color: #ffffff !important;
text-decoration: none !important;
box-shadow:
0 3px 9px rgba(0,0,0,.12);
transition:
transform .15s ease,
box-shadow .15s ease,
filter .15s ease;
}
.cdc-channel-icon svg {
width: 19px;
height: 19px;
fill: currentColor;
}
.cdc-channel-icon:hover {
transform: translateY(-1px) scale(1.04);
box-shadow:
0 5px 12px rgba(0,0,0,.16);
filter: brightness(1.03);
}
/* COLORI UFFICIALI */
.cdc-channel-whatsapp {
background: #25D366;
}
.cdc-channel-instagram {
background:
radial-gradient(
circle at 30% 107%,
#fdf497 0%,
#fdf497 5%,
#fd5949 45%,
#d6249f 60%,
#285AEB 90%
);
}
.cdc-channel-messenger {
background:
linear-gradient(
135deg,
#00B2FF 0%,
#006AFF 52%,
#A033FF 100%
);
}
/* MOBILE */
@media (max-width: 520px) {
.cdc-channel-bar {
gap: 8px;
padding: 8px 9px;
border-radius: 12px;
}
.cdc-channel-logo {
width: 30px;
height: 30px;
flex-basis: 30px;
}
.cdc-channel-text strong {
font-size: 11px;
max-width: 180px;
overflow: hidden;
text-overflow: ellipsis;
}
.cdc-channel-text span {
font-size: 8px;
}
.cdc-channel-links {
gap: 5px;
}
.cdc-channel-icon {
width: 32px;
height: 32px;
flex-basis: 32px;
}
.cdc-channel-icon svg {
width: 17px;
height: 17px;
}
}
/* TELEFONI MOLTO PICCOLI */
@media (max-width: 380px) {
.cdc-channel-text span {
display: none;
}
.cdc-channel-text strong {
max-width: 135px;
font-size: 10.5px;
}
.cdc-channel-logo {
width: 28px;
height: 28px;
flex-basis: 28px;
}
.cdc-channel-icon {
width: 30px;
height: 30px;
flex-basis: 30px;
}
}
